Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Toronto-Dominion Bank — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Toronto-Dominion Bank trades at $118.45 (market cap $200.57B). The key difference: Toronto-Dominion Bank is far larger — about 44.7× ACADIA Pharmaceuticals Inc.'s market cap, and Toronto-Dominion Bank pays a 2.67% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | TD | |
|---|---|---|
Market Cap | $4.49B | $200.57B |
Sector | Health | Financials |
52-Week High | $28.06 | $122.25 |
52-Week Low | $20.06 | $72.55 |
Enterprise Value | $3.69B | — |
Dividend Yield | — | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
TD stock trades at $121.43, up 1.79% today, with a bullish technical signal from moving averages. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.74 surpassing the $1.63 estimate. Revenue grew to $61.28 billion in 2025, and the net income margin improved to 33.51%. Analysts maintain a buy consensus with a $153 price target, and the company recently increased its dividend.
The outlook is positive given strong profitability, dividend growth, and analyst support, but risks include volatile cash flows from operations and rising debt-to-asset ratios. The stock offers value with a P/E of 20.1 and robust ROE of 12.59%, though investors should monitor credit performance amid economic softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
